Focused On-demand Library for Mitotic spindle assembly checkpoint protein MAD2A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q13257

UPID:

MD2L1_HUMAN

Alternative names:

Mitotic arrest deficient 2-like protein 1

Alternative UPACC:

Q13257; Q53F56; Q548X9; Q6IRW7; Q8IZX3

Background:

Mitotic spindle assembly checkpoint protein MAD2A, also known as Mitotic arrest deficient 2-like protein 1, plays a crucial role in cell division. It ensures that chromosomes are correctly aligned before a cell proceeds from metaphase to anaphase, by forming a complex that inhibits premature separation. This process is vital for genetic stability and cell viability.

Therapeutic significance:

Understanding the role of Mitotic spindle assembly checkpoint protein MAD2A could open doors to potential therapeutic strategies. Its pivotal function in cell cycle regulation highlights its potential as a target in cancer therapy, where cell division often goes awry.